This is a letter to the Editor concerning the recently published article by Zerem et al. The paper described a 12yo female with multisystem mitochondrial disorder (MID) due to the compound heterozygous variants c.1963_1964dupAT and p.Ile382Met in OPA1 manifesting phenotypically with congenital nystagmus, developmental delay, visual impairment, gait ataxia, epilepsy, a stroke-like episode (SLE) with encephalopathy and vomiting, and hearing impairment. This interesting case could be more meaningful by providing more information about the treatment of the SLE/stroke-like lesion (SLL), about the morphological characteristics of the SLL on MRI, and the results of prospective investigations for subclinical involvement of organs so far clinically unaffected.
Finsterer J (2017) Toxicity of antiepileptic drugs to mitochondria. Handb Exp Pharmacol 240:473–488CrossRefGoogle Scholar
Finsterer J, Laccone F (2019) Autosomal dominant optic atrophy plus due to the novel OPA1 variant c.1463G>C. Metab Brain Dis 34:1023–1027CrossRefGoogle Scholar
Ham M, Han J, Osann K, Smith M, Kimonis V (2019) Meta-analysis of genotype-phenotype analysis of OPA1 mutations in autosomal dominant optic atrophy. Mitochondrion 46:262–269CrossRefGoogle Scholar
Liskova P, Ulmanova O, Tesina P, Melsova H, Diblik P, Hansikova H, Tesarova M, Votruba M (2013) Novel OPA1 missense mutation in a family with optic atrophy and severe widespread neurological disorder. Acta Ophthalmol 91:e225–e231CrossRefGoogle Scholar
Steriade C, Andrade DM, Faghfoury H, Tarnopolsky MA, Tai P (2014) Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) may respond to adjunctive ketogenic diet. Pediatr Neurol 50:498–502CrossRefGoogle Scholar
Zerem A, Yosovich K, Rappaport YC, Libzon S, Blumkin L, Ben-Sira L, Lev D, Lerman-Sagie T (2019) Metabolic stroke in a patient with bi-allelic OPA1 mutations. Metab Brain Dis 34:1043–1048CrossRefGoogle Scholar